Table 4 Summary of multivariate Cox's regression analyses of securin immunoexpression performed in invasive breast carcinomas and in subgroups divided according to invasive ductal histology (IDC) and Ki-67 immunopositivity (low, <10%; high, ⩾10%)

From: Securin promotes the identification of favourable outcome in invasive breast cancer

 

n

P

HR

95% CI

All

257

0.028

2.3

1.1–5.0

 Ki-67<10%

106

0.031

5.1

1.2–22.7

 Ki-67⩾10%

134

0.617

  

IDC

211

0.051

  

 Ki-67<10%

84

0.024

13.1

1.4–121.3

 Ki-67⩾10%

118

0.719

  
  1. The results are based on the optimal cut-point determined at 1.5% of securin immunopositivity, derived from analysis of breast cancer-specific survival of the patient data. Axillary lymph node status, patient's age and tumour size at the time of diagnosis were used as covariates in multivariate analyses.
Back to article page